This study is in progress, not accepting new patients
Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCLA UCSF
- Dates
- study startedcompletion around
- Principal Investigator
- by Zev Wainberg (ucla)
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Zev Wainberg (ucla)
HS Clinical Professor, Medicine. Authored (or co-authored) 159 research publications
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Novartis Pharmaceuticals
- ID
- NCT02900651
- Phase
- Phase 1 research study
- Study Type
- Interventional
- Participants
- About 139 people participating
- Last Updated